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Background/aim: This article analyzes the incidence and characteristics of peripheral neuropathy in patients with impaired glucose
regulation (IGR).
Materials and methods: A total of 120 IGR patients and 60 healthy controls were enrolled. All subjects underwent nerve conduction
study (NCS) of large fibers and skin sympathetic response (SSR) and contact heat pain evoked potential (CHEP) testing of small fibers
with a Medtronic Keypoint machine (Medoc Ltd., Israel). IGR patients were evaluated using the Michigan Neuropathy Screening
Instrument (MNSI).
Results: The abnormal rates (MNSI >2) in IGR patients and NCS and SSR evaluations were 18.3%, 22.5%, and 39.2%, respectively. All
abnormal NCS findings were accompanied with abnormal SSR findings. Compared with the control group, the sensory nerve action
potential wave of the posterior tibial and sural nerve was decreased in the IGR group (P = 0.01, P = 0.00), the SSR wave was reduced in
the upper and lower limbs (P = 0.002, P = 0.00), and the CHEP wave was decreased in opisthenar and shank (P = 0.00). Compared with
the control group, the CHEP wave was decreased in the shank in the normal SSR group (P < 0.05) and in the opisthenar and shank in
the normal NCS group (P < 0.05).
Conclusion: : IGR patients have peripheral neuropathy characterized by impaired functions of large and small fibers focused on small
fiber and lower limb sensory nerves. CHEP can detect small fiber damage earlier than SSR and NCS.
Key words: Impaired glucose regulation, peripheral neuropathy, nerve conduction, skin sympathetic response, contact heat evoked
potential

1. Introduction
Impaired glucose regulation (IGR), also known as
prediabetes, is defined as the intermediate stage that is
higher than the normal value of blood glucose but lower
than the diabetes threshold. IGR consisted of impaired
fasting glucose (IFG) and impaired glucose tolerance
(IGT), and 5%–10% IGR patients may develop diabetes
mellitus (DM) per year. According to a report by the
International Diabetes Federation, it is predicted that the
number of global IGR patients will reach 471 million by
2035 (1). In China, the IGR population reached 148.2
million in 2010 (2). Peripheral neuropathy (PN) is one of
the three most prevalent complications of DM and 10%
of patients diagnosed with DM had accompanying PN
(3). Hence, there is a growing concern about the relation
between PN and IGR. At present, several researchers
have already demonstrated that IGT patients have

peripheral nerve lesions (4) and most of those studies were
carried out with the use of clinical neurologic score and
neuroelectrophysiological technologies.
In this study, we endeavor to analyze PN and its
characteristics using nerve conduction study (NCS)
to evaluate large fiber functions and skin sympathetic
response (SSR) and contact heat pain evoked potential
(CHEP) to evaluate small fiber functions. We hypothesized
that IGR patients have peripheral nerve lesions, which
may focus on small fibers, and that CHEP can detect small
fiber lesions earlier than SSR and NCS.
2. Materials and methods
2.1. Patients
According to the IGR diagnostic criteria recommended by
the World Health Organization in 2006 (5), 120 diagnosed
IGR patients admitted to our hospital from January 2015 to
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December 2016 were enrolled in this study. Among them,
there were 56 males and 64 females aged 35–81 (58.2 ± 8.2)
years. Subjects were considered to have IFG if the fasting
plasma glucose was between 6.1 and 6.9 mmol/L and the
2-h oral glucose tolerance test (OGTT) was less than 7.8
mmol/L, and subjects were considered to have IGT if
fasting blood glucose was less than 7.0 mmol/L and the
2-h OGTT was between 7.8 and 11.0 mmol/L.
Patients with the following diseases were excluded
from the study: 1) history of ischemic and hemorrhagic
cerebral vascular diseases; 2) cervical and lumbar disease
(nerve root compression, spinal stenosis, degeneration of
neck and lumbar spine); 3) toxic, infectious, nutritional,
or immune-mediated peripheral neuropathy; 4) severe
arteriovenous vascular disease (including venous
thrombosis and lymphangitis); 5) neuropathy induced
by toxic metabolites caused by renal failure; 6) ulcers,
infections, and edema of the foot; 7) single neuropathy
such as carpel and cubital tunnel syndrome; 8) other
diagnosed nondiabetic peripheral neuropathies .
Sixty healthy volunteers were selected as the control
group, including 28 males and 32 females aged 43–80 years
(59.9 ± 7.0).
This study was approved by the Tianjin Third Central
Hospital Ethics Committee, and all subjects acknowledged
the burden of the intervention and provided informed
consent.
2.2. Methods
Subjects lay supine in a quiet room with eyes closed at room
temperature of about 22–25 °C. NCS was performed on the
median nerve, ulnar nerve, posterior tibial nerve, peroneal
nerve, and sural nerve; SSR on the limbs; and CHEP on
the unilateral opisthenar and shank using a Medtronic
Keypoint machine (Medoc Ltd., Israel).
Participants from both groups were randomly assigned
numbers in the examinations and the data were collected by
two neurologists without knowing the patient information.
2.3. Sports conduction
Saddle-shaped electrodes were used for stimulation and
the surface electrode values were recorded. Measured
parameters included complex muscle action potential
(CMAP) wave and motor conduction velocity (MCV).
2.4. Sensory conduction
Ring electrode stimulation was performed and the saddleshaped electrode value was recorded by orthodromic
method. Measured parameters included sensory
conduction velocity (SCV) and sensory nerve action
potential (SNAP) from the median nerve of finger 1–wrist,
ulnar nerve of finger 5–wrist, posterior tibial nerve of toe
1–malleolus medialis, and sural nerve ankle–lower 1/3 on
the lateral shank.
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2.5. SSR
Saddle-shaped electrodes stimulated the median nerve
of the unilateral wrist with 50 mA for 0.2 ms. Electrodes
from the centers of the palms and soles on both sides were
recorded. Electrodes from the dorsal hand and sole served
as references. Measured parameters included latency and
amplitude. Detailed methods and normal values of NCS
and SSR results have been previously discussed (6,7).
2.6. CHEP
A single pulse consecutively stimulated the unilateral
dorsum of the hand and the lateral skin of the shank
5 times with a basic temperature of 32 °C and peak
temperature of 51 °C by the use of a PATHWAY pain and
sensory evaluation system (Medoc Ltd.). According to the
standard 10-20 system, midline electrodes (Cz point) of
a 64-channel surface recording cap were recorded, and
the electrodes from the FPz point with impedance of less
than 5 kΩ served as references. Measured parameters
included N wave latency (from the start of stimulation to
the start of the negative wave; data presented as ms) and
N-P wave (the peak value from the max negative wave to
the max positive wave; data presented as µV). Detailed
methodology and instrument settings were mentioned in
a previous study (8).
2.7. Michigan Neuropathy Screening Instrument (MNSI)
The MNSI was scored by the same neurologist regarding
foot appearance, ankle reflex, and large toe vibration.
MNSI values >2 are considered abnormal.
2.8. Statistical analysis
SPSS 20.0 (IBM Corp., Armonk, NY, USA) was used for
statistical analysis and data were presented as mean ±
standard deviation. Comparisons between two groups used
the t-test, comparison among three groups used ANOVA,
and comparison between groups used the LSD test. P <
0.05 indicates statistical significance. Power analysis was
performed with PASS 15.0 (NCSS, Kaysville, UT, USA).
3. Results
3.1. Clinical and neural electrophysiological evaluation
on IGR patients
The rates of abnormal MNSI scores (>2) in IGR, NCS,
and SSR were 18.3%, 22.5%, and 39.2%, respectively. All
patients with abnormal NCS results had abnormal SSR
results; therefore, the PN incidence in IGR patients can be
considered as 39.2%.
In the IGR group, the prevalence of decreasing or
even disappearing ankle reflex was 33.3% (40/120); the
prevalence of clinical symptoms including pain, numbness,
and burning sensation was 16.7% (20/120); the prevalence
of reduction or absence of large toe vibration was 20.8%
(25/120); and the prevalence of reducing or disappearing
monofilament sensation was 19.2% (23/120).
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3.2. Comparison between IGR group and control group
regarding NCS, SSR, and CHEP results
Compared with the control group, SNAP amplitude in the
IGR group was decreased for posterior tibial nerve toe 1–
ankle and sural nerve ankle–shank (1.51 ± 1.3 vs. 2.01 ±
1.5 µV, P = 0.01, power test = 1; 6.5 ± 1.9 vs. 10.5 ± 2.0 µV,
P = 0.00, power test = 1, respectively), SSR amplitude was
decreased for the upper and lower limbs (1463 ± 1140 vs.
2124 ± 1346 µV, P = 0.002, power test = 1; 892 ± 387 vs.
531 ± 501 µV, power test = 1, respectively], and CHEP N-P
amplitude was decreased for the opisthenar and shank
(52.4 ± 12.6 vs. 63.0 ± 10.0 µV, P = 0.00, power test = 1;
29.3 ± 12.1 vs. 44.7 ± 12.5 µV, P = 0.00, power test = 1,
respectively). Details are presented in Tables 1 and 2 and
Figures 1 and 2.
3.3. Comparison of CHEP results for opisthenar and
shank among the SSR, NCS, and control groups
According to the results of the NCS and SSR, IGR patients
were divided into 4 groups: 73 in the normal SSR group
(SSRN), 47 in the abnormal SSR group (SSRA), 93 in the

normal NCS group (NCSN), and 27 in the abnormal NCS
group. CHEP results of the four groups were compared.
CHEP amplitude on the shank in the SSRN group was
decreased compared with the control group (33.1 ± 18.9
vs. 44.7 ± 12.5 µV, P < 0.05, power test = 0.99); CHEP
amplitude on opisthenar and the shank in the SSRA group
declined compared with the control group (42.9 ± 16.5 vs.
63.0 ± 10.8 µV, P < 0.05, power test = 1; 25.5 ± 19.1 vs. 44.7
± 12.5, P < 0.05, power test = 1) and the SSRN group (42.9
± 16.5 vs. 62.0 ± 13.3, P < 0.05, power test = 1; 25.5 ± 19.1
vs. 33.1 ± 18.9 µV, P < 0.05, power test = 0.99); CHEP wave
on the opisthenar and the shank were decreased in the
NCSN group compared with control group (52.4 ± 15.3
vs. 63.0 ± 10.8 µV, P < 0.05, power test = 1; 28.4 ± 17.4 vs.
44.7 ± 12.5 µV, P < 0.05, power test = 1); and CHEP wave
on the opisthenar and the shank in the NCSA group was
decreased and the latency was extended compared with
the control group (38.7 ± 13.5 vs. 63.0 ± 10.8 µV, P < 0.05,
power test = 1; 44.7 ± 12.5 vs. 21.9 ± 13.9 µV, P < 0.05,
power test = 1) and the NCSN group (38.7 ± 13.5 vs. 52.4

Table 1. Results of NCS in the IGR group and control group (mean ± SD).
GR
n = 120

Control group
n = 60

t/u value

P-value

CMAP amplitude (mV)

10.1 ± 2.2

9.7 ± 2.0

1.70

0.09

MCV (wrist–elbow) (m/s)

58.9 ± 5.1

59.5 ± 3.4

–1.17

0.24

Finger 1–wrist SNAP amplitude (µV)

22.8 ± 8.5

24.2 ± 8.7

–1.03

0.15

Finger 1–wrist SCV (m/s)

52.2 ± 5.8

52.9 ± 5.6

–1.31

0.19

CMAP amplitude (mV)

10.4 ± 1.6

10.5 ± 1.5

–0.62

0.53

MCV (wrist–elbow) (m/s)

62.0 ± 2.9

63.6 ± 3.7

0.04

0.97

Finger 5–wrist SNAP amplitude (µV)

10.5 ± 3.6

10.7 ± 3.2

–0.38

0.35

Finger 5–wrist SCV (m/s)

57.8 ± 6.2

57.3 ± 5.5

0.23

0.81

DML (ms)

3.5 ± 0.7

3.5 ± 0.8

0.23

0.81

CMAP amplitude (mV)

13.3 ± 4.20

13.5 ± 4.7

–0.23

0.81

Toe 1–ankle SNAP amplitude (µV)

1.51 ± 1.3

2.01 ± 1.5

–2.17

0.01*

Toe 1–ankle SCV (m/s)

48.4 ± 6.2

49.4 ± 7.8

–1.03

0.30

CMAP amplitude (mV)

5.5 ± 1.8

5.7 ± 1.7

–0.86

0.39

MCV (Ankle–small head) (m/s)

49.2 ± 3.7

49.5 ± 4.6

–0.56

0.57

Ankle–shank SNAP amplitude (µV)

6.5 ± 1.9

10.5 ± 2.0

–12.9

0.00*

Ankle–shank SCV (m/s)

58.6 ± 5.6

59.0 ± 6.2

–0.41

0.68

Item
Median nerve

Ulnar nerve

Posterior tibial nerve

Peroneal nerve

Sural nerve

*Statistical significance (P < 0.05).
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Table 2. Results of SSR and CHEP in IGR group and control group (mean ± SD).
IGR
n = 120

Control group
n = 60

t-value

P-value

Upper limb latency (ms)

1385 ± 176

1356 ± 123

1.51

0.13

Upper limb amplitude (µV)

1463 ± 1140

2124 ± 1346

–3.21

0.002*

Lower limb latency (ms)

1820 ± 250

1891 ± 270

–1.11

0.16

Lower limb amplitude (µV)

531 ± 501

892 ± 387

–6.18

0.00*

Hand back stimulation N wave latency (ms)

342.5 ± 16.5

340.0 ± 17.8

0.66

0.50

N-P wave amplitude (µV)

52.4 ± 12.6

63.0 ± 10.0

3.09

0.00*

Calf irritation N wave latency (ms)

447.5 ± 21.3

446.7 ± 12.9

0.19

0.84

N-P wave amplitude (µV)

29.3 ± 12.1

44.7 ± 11.9

5.84

0.00*

Item
SSR

CHEP

*Statistical significance (P < 0.05).

Figure 1. CHEP results from shank simulation in the IGR group (A) and control
group (B). Compared with the control group, CHEP-N wave latency was normal,
but N-P wave amplitude decreased in the IGR group.

1210

LIU et al. / Turk J Med Sci

Figure 2. SSR results from limb stimulation in the IGR group (A) and control
group (B). Compared with the control group, SSR latency was normal but
amplitude was decreased in the IGR group.

± 15.3 µV, P < 0.05, power test = 0.99; 21.9 ± 13.9 vs.
28.2 ± 14.4 µV, P < 0.05, power test = 0.87). Details are
presented in Tables 3 and 4.
4. Discussion
PN is one of the most common complications of DM, and
there is controversy regarding the presence of PN in IGR
patients. Novella et al. conceded that PN may be related to

prediabetes, which occurs in the early stage of diabetes (9).
By the use of electrophysiological technologies, Kannan
et al. (10) confirmed the hypothesis that peripheral
nerve lesions can be detected in IGT patients. However,
some scholars still doubt such correlations (11). Different
detection methods may also lead to different prevalences
of prediabetes. Ziegler et al. (12) detected 24.3% risk
of PN in prediabetic patients with MNSI scores of >2 as
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Table 3. Results of CHEP for opisthenar and shank in SSRA,
SSRN, and control groups (mean ± SD).
Group

n

Hand back
stimulation

Calf irritation

N wave latency (ms)

Table 4. Results of CHEP for opisthenar and shank in NCSA,
NCSN, and control groups (mean ± SD).
Group

n

Hand back
stimulation

Calf irritation

N wave latency (ms)

SSRA group

47

342.5 ± 16.9

450.6 ± 22.7

NCSA group

27

363.6 ± 24.2** 461.1 ± 22.7**

SSRN group

73

342.6 ± 19.8

444.7 ± 23.0

NCSN group

93

345.5 ± 18.9

448.5 ± 25.7

Control group

60

340.0 ± 17.9

446.7 ± 12.5

Control group

60

340.0 ± 17.9

446.7 ± 12.5

N-P wave amplitude (µV)

N-P wave amplitude (µV)

SSRA group

59

42.9 ± 16.5**

25.5 ± 19.1**

NCSA group

27

38.7 ± 13.5**

21.9 ± 13.9**

SSRN group

61

62.0 ± 13.3

33.1 ± 18.9*

NCSN group

61

52.4 ± 15.3*

28.2 ± 14.4*

Control group

40

63.0 ± 10.8

44.7 ± 12.5

Control group

60

63.0 ± 10.8

44.7 ± 12.5

*Compared with the control group, P < 0.05.
**Compared with the control group and SSRN group, P < 0.05.

*Compared with the control group, P < 0.05.
**Compared with the control group and NCSN group, P < 0.05.

the diagnostic criterion for PN. A community study in
China (13) evaluated 268 IGR cases and 91 DM cases by
MNSI, revealing that the PN prevalences in IGR and DM
patients were 24.6% and 36.6%, respectively. In addition,
more peripheral nerve damage can be detected with the
application of neurophysiological technologies. Kannan et
al. (10) found that the prevalence of IGT patients with PN
was 32.8% by using NCS, quantitative sensory measurement
(QST), and autonomic testing. In the current study, we
analyzed the abnormal rate in IGR patients and the patients
went through NCS and SSR tests based on MNSI scores (>2).
We found that the prevalences of patients with abnormal
MNSI scores (>2) were 18.3%, 22.5%, and 39.2% in the total
IGR patients, the NCS group, and the SSR group. Abnormal
NCS results were always accompanied with abnormal SSR
results; therefore, we speculated that the prevalence of PN
in the IGR patients was 39.2%.
Then we compared the results of NCS, SSR, and CHEP
between IGR patients and healthy volunteers. NCS was
used to evaluate the function of large myelinated nerve fiber
Aα while SSR and CHEP were used to evaluate small nerve
fibers of class C and Aδ. As a result, we found that in IGR
patients, SNAP amplitude decreased in the posterior tibial
nerve and sural nerve, SSR amplitude decreased in the upper
and lower extremities, and CHEP N-P wave amplitude
decreased in the opisthenar and the shank. All these
outcomes indicated that IGR patients have peripheral nerve
damage focusing on the small nerve fibers and lower limb
sensory fibers, with the characteristics of axon impairment
and length dependence. Green et al. (14) found that lesions
in IGT patients were focused on C class myelinated fibers.
Isak et al. (15) detected that GT patients only had reduction
of the SSR wave compared with a control group by NCS,
SSR, and autonomic nerve function evaluation, which

suggested that PN would appear as small fiber neuropathy at
an early stage. Kannan et al. (10) evaluated peripheral nerve
lesions in patients with prediabetes using NCS, autonomic
function evaluation, and QST and found that prediabetic
patients had lesions not only on small fibers but also on
large sensory fibers, which is consistent with our results.
Finally, we compared the CHEP results of the SSRN,
SSRA, NCSN, and NCSA groups based on MNSI scores and
demonstrated that CHEP can detected small fiber lesions
in the early phrase in IGR patients better than SSR and
NCS, and lesions will become worse if the SSR and NCS
evaluations deteriorate to abnormal. As a noninvasive
technique detecting small fiber pathways from the skin to
the cerebral cortex, CHEP can reflect the fiber function
of Aδ and class C, which is also more stable and objective
than SSR (16). Our previous studies (8,17) found that CHEP
can detect small fiber lesions earlier in diabetic patients,
as the CHEP N-P wave was decreased in forearms and
shanks in the NCSN group. Wong et al. (17) found that,
compared with a healthy control group, the CHEP N1-P1
wave was decreased in lateral shanks in a DM group with or
without lower extremity symptoms, suggesting that N1-P1
amplitude reflecting an early stage of small fibrosis can be
detected by CHEP.
However, there is still no consensus on the mechanism
of peripheral nerve damage in IGR patients. Some
researchers suggest that it is similar to the mechanism of
diabetic neuropathy, which includes chronic hyperglycemia,
dyslipidemia, microangiopathy, and metabolic syndrome
(18,19). On the other hand, some studies propose that
rather than increasing blood glucose, prediabetic PN is
associated with abnormal insulin signal, dyslipidemia, and
endoplasmic reticulum stress (20). Besides, “small fiber”
refers to the unmyelinated or myelinated sensory fibers that
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are susceptible to any damage, which is why the current
study and previous researchers detected that peripheral
nerve lesions were focused on small nerve fibers.
In summary, this study demonstrated that the prevalence
of PN in IGR patients was 39.2%, that neurophysiological
technologies can detect early peripheral neuropathy
characterized by lesions on large and small fibers and
focused on the small fibers and lower limb sensory fibers,
and CHEP can detect small fiber lesions in IGR patients
earlier than SSR and NCS. Therefore, we suggest that more
attention be paid to preventing and treating peripheral
neuropathy in the early stage of diabetes, since those
lesions are relatively mild and easier to cure.
However, there are still some limitations of this study.
First, SSR and CHEP can be used to evaluate class C and

Aδ fibers, but they are not the best for detecting small
fibers, which are susceptible to many factors. Second,
intradermal nerve fiber density can serve as the golden
standard for detecting small fibers, which is an invasive
form of examination. However, further studies can apply
this method to convey more accurate results. Third, this
study only focused on the symptoms and characteristics
of PN in IGR patients; therefore, further studies should
pay attention to the risk factors and the mechanism of
this disease.
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